Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
No randomised trial exists and the induction-response strategy rests on one centre's series.
Enasidenib's activity in IDH2-mutant sinonasal carcinoma is unproven.
Most patients still die of the disease within a few years.
Orbital and skull base surgery and radiotherapy carry heavy functional costs.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.